Citations

Clear

163 citation(s) found for "Sharp, H L".

Abstract 10822: Familial Hypercholesterolemia in the EMERGE Network: 1-Year Outcomes After Return of Results
Kochan, David C., Perez, Emma , Anderson, Katherine , Salvati, Zachary , Hebbring, Scott J. , Gibbs, Richard A. , Linder, Jodell E. , Roden, Dan M. , Manolio, Teri A. , Sherafati, Alborz , Dikilitas, Ozan , Saadatagah, Seyedmohammad , Satterfield, Benjamin A. , Jones, Laney K , Sharp, Richard R. , Sturm, Amy C. , Zouk, Hana , Venner, Eric , Chung, Wendy K. , Peterson, Josh F. , Jarvik, Gail P. , Rehm, Heidi L. , Roden, Dan M. , Williams, Marc S , Kullo, Iftikhar J.

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.10822 Get It

Introduction: Relatively little is known about outcomes following return of secondary findings detected in large scale sequencing projects. We assessed 1-year outcomes following return of pathogenic/likely pathogenic (P/LP) variants associated with familial hypercholesterolemia (FH) in phase III of the eMERGE network (2015-2019). Methods: Adult participants (n=18,544) at 7 sites were enrolled in a prospective cohort study to study the clinical impact of returning results from targeted sequencing of 68 actionable genes, including LDLR , APOB , and PCSK9 . Process, intermediate, and/or clinical outcomes within 1-year after return of results (RoR) were ascertained by electronic health record (EHR) review. A process outcome was defined as referral to a specialist or ordering new tests, including lipid profile and screening tests for coronary heart disease. An intermediate outcome was defined as new diagnosis of FH or atherosclerotic cardiovascular disease. A clinical outcome was defined as initiation or change in lipid-lowering medication. The primary outcomes were a new diagnosis of FH and modification of lipid lowering therapy. Results: Results were returned to 134 individuals, and data for 119 participants were available for the outcomes analysis. Process (86%), intermediate (49%), and/or clinical (26%) outcomes occurred in 92% of participants. Process outcomes included 72% with new tests ordered and 61% referred to a specialist. Before RoR, 86.5% of individuals with FH associated P/LP variants had a diagnosis of hypercholesterolemia but only 17.6% had a diagnosis of FH; 89% were on a statin but only 58% were on a high intensity statin. Following RoR, 44% (52/119) received a new diagnosis of FH. Lipid lowering treatment was modified in 26% (31/119), including initiation of a statin in 5%, increasing statin dose in 13%, and adding ezetimibe or a PCSK9 inhibitor in 12.6%. Conclusions: In a multisite cohort of EHR-linked biobanks, monogenic FH was underdiagnosed (only 17.6% had a specific diagnosis) and undertreated (only 58% were on a high intensity statin); 44% of participants received a new diagnosis of FH and 26% had lipid lowering treatment modified after RoR. These results highlight the clinical utility of returning FH variants in EHR-linked biobanks.
Ethical Aspects of Machine Listening in Healthcare
Stroud, Austin M. , Pacyna, Joel E. , Sharp, Richard R. , Sharp, Richard R

Mayo Clinic

The American Journal of Bioethics | May 2, 2023 | Volume: 23 | Issue: 5 | Pages: 1-3

10.1080/15265161.2023.2199646 | PMID 37130383 Get It

Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system
Bakri, Sophie J. , Bektas, Meryem , Sharp, Darcie, Luo, Roger , Sarda, Sujata P. , Khan, Shahnaz

Mayo Clinic

Journal of Managed Care & Specialty Pharmacy | May 1, 2023 | Volume: 29 | Issue: 5-a Suppl | Pages: S2-S11

10.18553/jmcp.2023.29.5-a.s2 | PMID 37125931 Get It

Familial Hypercholesterolemia in the Electronic Medical Records and Genomics Network: Prevalence, Penetrance, Cardiovascular Risk, and Outcomes After Return of Results
Dikilitas, Ozan , Sherafati, Alborz , Saadatagah, Seyedmohammad , Kochan, David C., Anderson, Katherine , Chung, Wendy K. , Hebbring, Scott J. , Salvati, Zachary , Sharp, Richard R. , Sturm, Amy C. , Gibbs, Richard A. , Rowley, Robb , Linder, Jodell E. , Perez, Emma , Peterson, Josh F. , Jarvik, Gail P. , Roden, Dan M. , Manolio, Teri A. , Satterfield, Benjamin A , Anderson, Katherine C , Chung, Wendy K. , Salvati, Zachary M , Sharp, Richard R , Sturm, Amy C , Rowley, Robb , Venner, Eric , Linder, Jodell E , Jones, Laney K , Peterson, Josh F , Jarvik, Gail P , Rehm, Heidi L , Zouk, Hana , Roden, Dan M. , Williams, Marc S , Manolio, Teri A , Kullo, Iftikhar J , Dikilitas, Ozan , Satterfield, Benjamin A. , Venner, Eric , Rehm, Heidi L. , Kullo, Iftikhar J.

Mayo Clinic

Circulation: Genomic and Precision Medicine | February 22, 2023 | Volume: 16 | Issue: 2 | Pages: No page available

10.1161/circgen.122.003816 | PMID 37071725 Get It

Background: The implications of secondary findings detected in large-scale sequencing projects remain uncertain. We assessed prevalence and penetrance of pathogenic familial hypercholesterolemia (FH) variants, their association with coronary heart disease (CHD), and 1-year outcomes following return of results in phase III of the electronic medical records and genomics network. Methods: Adult participants (n=18 544) at 7 sites were enrolled in a prospective cohort study to assess the clinical impact of returning results from targeted sequencing of 68 actionable genes, including LDLR , APOB , and PCSK9 . FH variant prevalence and penetrance (defined as low-density lipoprotein cholesterol >155 mg/dL) were estimated after excluding participants enrolled on the basis of hypercholesterolemia. Multivariable logistic regression was used to estimate the odds of CHD compared to age- and sex-matched controls without FH-associated variants. Process (eg, referral to a specialist or ordering new tests), intermediate (eg, new diagnosis of FH), and clinical (eg, treatment modification) outcomes within 1 year after return of results were ascertained by electronic health record review. Results: The prevalence of FH-associated pathogenic variants was 1 in 188 (69 of 13,019 unselected participants). Penetrance was 87.5%. The presence of an FH variant was associated with CHD (odds ratio, 3.02 [2.00–4.53]) and premature CHD (odds ratio, 3.68 [2.34–5.78]). At least 1 outcome occurred in 92% of participants; 44% received a new diagnosis of FH and 26% had treatment modified following return of results. Conclusions: In a multisite cohort of electronic health record–linked biobanks, monogenic FH was prevalent, penetrant, and associated with presence of CHD. Nearly half of participants with an FH-associated variant received a new diagnosis of FH and a quarter had treatment modified after return of results. These results highlight the potential utility of sequencing electronic health record–linked biobanks to detect FH.
Examining the Impact of Polygenic Risk Information in Primary Care
Pacyna, Joel E. , Ennis, Jackson S. , Sharp, Richard R. , Sharp, Richard R , Kullo, Iftikhar J.

Mayo Clinic

Journal of Primary Care & Community Health | January 31, 2023 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/21501319231151766 | PMID 36718804 Get It

Background: Polygenic risk testing examines variation across multiple genes to estimate a risk score for a particular disease, including risk scores for many common, chronic health conditions. Although polygenic risk information (PRI) may be a promising tool for enhancing preventive counseling and facilitating early identification of disease, its potential impact on primary-care encounters and disease prevention efforts has not been well characterized. Methods: We conducted in-depth, semi-structured interviews of patients to assess their understandings of PRI and their beliefs about its relevance to disease prevention. Results: We completed interviews with 19 participants. Participants described enthusiasm for the generation of PRI and recognized its utility for disease prevention. Participants also described the value of PRI as limited if not corroborated by non-genetic risk factors. Finally, participants noted that PRI, by itself, would be insufficient as a trigger for initiating many preventive interventions. Conclusion: PRI has the potential to become an important tool in primary care. However, patient views about PRI as well as the complexities of disease prevention in the primary care context may limit the impact of PRI on disease prevention.
Ethical Aspects of Prodromal Synucleinopathy Prognostic Counseling
Stefani, Ambra , Kotagal, Vikas , Ju, Yo‐El S. , Louis, Erik K. St. , Sharp, Richard, St Louis, E K , Stefani, Ambra , Mozersky, Jessica T. , Högl, Birgit , Ingravallo, Francesca , Avidan, Alon Y. , Sharp, Richard R. , Videnovic, Aleksandar , Schenck, Carlos H.

Mayo Clinic

Seminars in Neurology | January 25, 2023 | Volume: 43 | Issue: 01 | Pages: 166-177

10.1055/a-2019-0245 | PMID 36693433 Get It

AbstractAlpha-synucleinopathies can be identified in their prodromal phase, raising several ethical issues. In this review, we first provide definitions of prodromal α-synucleinopathies and discuss the importance of distinguishing between prodromes and risk factors. Next, we discuss the implications of a diagnosis of prodromal α-synucleinopathy and considerations regarding prognostic counseling in both clinical and research settings. We review available data on patient preferences regarding disclosure as well as providers' perspectives. We examine the pros and cons of disclosing a diagnosis of prodromal α-synucleinopathy, taking into consideration the differences between clinical and research settings. Asking about willingness to know in clinical and research settings and the shared decision-making process applied to prognostic counseling is discussed. Concerning research settings, ethical aspects regarding clinical trials are addressed. Availability of direct-to-consumer technologies will likely lead to novel contexts requiring prognostic counseling, and future neuroprotective or neuromodulating treatments may require further considerations on the timing, role, and importance of prognostic counseling. Recommendations on how to address ethical gaps should be a priority for patients, medical professional societies, and research workgroups. Ethical issues must be considered as an integral part of the overall clinical and research approach to prodromal synucleinopathies.
Patient and Physician Decisional Factors Regarding Hypercalcemia of Malignancy Treatment: A Novel Mixed-Methods Study
Bassatne, Aya , Piggott, Thomas , Rahme, Maya , Fuleihan, Ghada El‐Hajj , Murad, Mohammad H, El-Hajj Fuleihan, Ghada , Piggott, Thomas , Murad, M. Hassan , Drake, Matthew T.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 22, 2022 | Volume: 108 | Issue: 3 | Pages: 563-584

10.1210/clinem/dgac630 | PMID 36545699 Get It

AbstractBackgroundIntegrating shared decision making between patients and physicians and incorporating their values and preferences in the development of clinical practice guidelines (CPGs) is of critical importance to optimize CPG implementation and treatment adherence. This applies to many debilitating diseases, including hypercalcemia of malignancy (HCM).ObjectiveEvaluate patient and physician values, preferences, and attitudes to better inform CPGs to treat HCM in adults.MethodsWe followed a mixed-methods approach. We conducted a systematic review using 5 databases to identify studies reporting on patient and physician values, costs and resources, feasibility, acceptability, and equity regarding HCM treatment. We also gathered data from different countries on the cost of multiple treatment modalities. We collected data on outcome prioritization from the CPG Working Group. Similarly, we collected data from patients with HCM regarding outcome prioritization and administered a questionnaire to evaluate their attitudes and perceptions toward treatment as well as treatment acceptability and feasibility.ResultsIn the systematic review, we included 2 cross-sectional surveys conducted on the same population of physicians who agreed that treating HCM alleviates symptoms and improves quality of life; however, harms and benefits should be thoroughly considered when deciding on the duration of treatment. We also included 2 studies on cost showing that intravenous (IV) bisphosphonate is more cost-effective than a combination of IV bisphosphonate and calcitonin and administration of IV zoledronic acid at home is more cost-effective than other IV bisphosphonates. The cost of zoledronic acid, denosumab, and cinacalcet varied widely among countries and types (brand vs generic). Both the CPG Working Group and patients with HCM agreed that the most important outcomes when deciding on treatment were survival and resolution of HCM, but there was some variability in the ratings for other outcomes.ConclusionUsing mixed methods, CPG developers can obtain meaningful information regarding evidence to decision criteria. In the case of HCM CPGs, this approach has provided the required contextual information and supported the development of evidence-based recommendations.
A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults
Seisa, Mohamed O. , Nayfeh, Tarek , Firwana, Mohammed , Saadi, Samer , Mushannen, Ahmed, Shah, Sahrish, Rajjoub, Noora S., Farah, Magdoleen H. , Fuleihan, Ghada El‐Hajj , Hasan, Bashar , Shah, Sahrish H, Drake, Matthew T , Murad, M Hassan , El-Hajj Fuleihan, Ghada , Nayfeh, Tarek , Saadi, Samer , Farah, Magdoleen H , Firwana, Mohammed M , Hasan, Bashar , Prokop, Larry J. , Wang, Zhen , Drake, Matthew T. , Murad, M. Hassan

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 22, 2022 | Volume: 108 | Issue: 3 | Pages: 585-591

10.1210/clinem/dgac631 | PMID 36545700 Get It

AbstractContextHypercalcemia is a common complication of malignancy that is associated with high morbidity and mortality.ObjectiveTo support development of the Endocrine Society Clinical Practice Guideline for the treatment of hypercalcemia of malignancy in adults.MethodsWe searched multiple databases for studies that addressed 8 clinical questions prioritized by a guideline panel from the Endocrine Society. Quantitative and qualitative synthesis was performed. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess certainty of evidence.ResultsWe reviewed 1949 citations, from which we included 21 studies. The risk of bias for most of the included studies was moderate. A higher proportion of patients who received bisphosphonate achieved resolution of hypercalcemia when compared to placebo. The incidence rate of adverse events was significantly higher in the bisphosphonate group. Comparing denosumab to bisphosphonate, there was no significant difference in the rate of patients who achieved resolution of hypercalcemia. Two-thirds of patients with refractory/recurrent hypercalcemia of malignancy who received denosumab following bisphosphonate therapy achieved resolution of hypercalcemia. Addition of calcitonin to bisphosphonate therapy did not affect the resolution of hypercalcemia, time to normocalcemia, or hypocalcemia. Only indirect evidence was available to address questions on the management of hypercalcemia in tumors associated with high calcitriol levels, refractory/recurrent hypercalcemia of malignancy following the use of bisphosphonates, and the use of calcimimetics in the treatment of hypercalcemia associated with parathyroid carcinoma. The certainty of the evidence to address all 8 clinical questions was low to very low.ConclusionThe evidence summarized in this systematic review addresses the benefits and harms of treatments of hypercalcemia of malignancy. Additional information about patients’ values and preferences, and other important decisional and contextual factors is needed to facilitate the development of clinical recommendations.
Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline
Fuleihan, Ghada El‐Hajj , Clines, Gregory A. , Hu, Mimi I. , Marcocci, Claudio , Murad, M. Hassan , Piggott, Thomas , Poznak, Catherine Van , Wu, Joy Y. , Drake, Matthew T. , El-Hajj Fuleihan, Ghada , Van Poznak, Catherine , Murad, M Hassan , Drake, Matthew T , Piggott, Thomas

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 22, 2022 | Volume: 108 | Issue: 3 | Pages: 507-528

10.1210/clinem/dgac621 | PMID 36545746 Get It

Abstract Background Hypercalcemia of malignancy (HCM) is the most common metabolic complication of malignancies, but its incidence may be declining due to potent chemotherapeutic agents. The high mortality associated with HCM has declined markedly due to the introduction of increasingly effective chemotherapeutic drugs. Despite the widespread availability of efficacious medications to treat HCM, evidence-based recommendations to manage this debilitating condition are lacking. Objective To develop guidelines for the treatment of adults with HCM. Methods A multidisciplinary panel of clinical experts, together with experts in systematic literature review, identified and prioritized 8 clinical questions related to the treatment of HCM in adult patients. The systematic reviews (SRs) queried electronic databases for studies relevant to the selected questions. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the certainty of evidence and make recommendations. An independent SR was conducted in parallel to assess patients' and physicians' values and preferences, costs, resources needed, acceptability, feasibility, equity, and other domains relevant to the Evidence-to-Decision framework as well as to enable judgements and recommendations. Results The panel recommends (strong recommendation) in adults with HCM treatment with denosumab (Dmab) or an intravenous (IV) bisphosphonate (BP). The following recommendations were based on low certainty of the evidence. The panel suggests (conditional recommendation) (1) in adults with HCM, the use of Dmab rather than an IV BP; (2) in adults with severe HCM, a combination of calcitonin and an IV BP or Dmab therapy as initial treatment; and (3) in adults with refractory/recurrent HCM despite treatment with BP, the use of Dmab. The panel suggests (conditional recommendation) the addition of an IV BP or Dmab in adult patients with hypercalcemia due to tumors associated with high calcitriol levels who are already receiving glucocorticoid therapy but continue to have severe or symptomatic HCM. The panel suggests (conditional recommendation) in adult patients with hypercalcemia due to parathyroid carcinoma, treatment with either a calcimimetic or an antiresorptive (IV BP or Dmab). The panel judges the treatments as probably accessible and feasible for most recommendations but noted variability in costs, resources required, and their impact on equity. Conclusions The panel's recommendations are based on currently available evidence considering the most important outcomes in HCM to patients and key stakeholders. Treatment of the primary malignancy is instrumental for controlling hypercalcemia and preventing its recurrence. The recommendations provide a framework for the medical management of adults with HCM and incorporate important decisional and contextual factors. The guidelines underscore current knowledge gaps that can be used to establish future research agendas.
Patient values and preferences regarding prognostic counseling in isolated REM sleep behavior disorder
Gossard, Thomas , Teigen, Luke, Yoo, Seeley , Timm, Paul, Jagielski, Jack T. , Bibi, Noor, Feemster, John, Steele, Tyler, Carvalho, Diego Z. , Junna, Mithri R. , Lipford, Melissa C. , Peikert, Maja Tippmann, McCarter, Stuart J. , Silber, Michael H. , Hirsch, Jessica R. , Sharp, Richard R. , Louis, Erik K. St. , Gossard, Thomas R , Jagielski, Jack , LeClair-Visonneau, Laurene , Boeve, Brad , Hirsch, Jessica, St Louis, E K , Sharp, Richard R , Carvalho, Diego Z , McCarter, Stuart J , Leclair‐Visonneau, Laurène , Boeve, Bradley F.

Mayo Clinic

Sleep | October 19, 2022 | Volume: 46 | Issue: 1 | Pages: No page available

10.1093/sleep/zsac244 | PMID 36259668 Get It

Abstract Study Objectives Isolated REM sleep behavior disorder (iRBD) carries a high lifetime risk for phenoconversion to a defined neurodegenerative disease (NDD) including Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. We aimed to examine iRBD patient values and preferences regarding prognostic counseling. Methods One hundred thirteen iRBD patient participants enrolled in the Mayo Clinic iRBD Patient Registry were sent an email survey concerning their values and preferences concerning NDD prognostic counseling and their experiences following diagnosis with iRBD. Results Of 81 respondents (71.7% response rate), the majority were men (74.0%) with an average age of 65.7 (±9.7) years. Responses indicated a strong preference toward receiving prognostic information about possible future NDD development. 92.5% of respondents felt knowledge concerning personal NDD risk was important, while 87.6% indicated prognostic discussions were important to maintaining trust in their physician. 95.7% indicated a desire for more information, while only 4.3% desired less information regarding their NDD prognostic risk. Most respondents strongly agreed that prognostic information was important to discuss with their family and friends and inform future life planning, and most expressed interest in learning more about future neuroprotective therapies and symptomatic treatments for parkinsonism and dementia. Conclusions Most iRBD patients indicated strong preferences for disclosure of NDD prognostic risk and indicated that prognostic information was important for family discussions and future life planning. Future broader surveys and qualitative studies of clinic-based and ultimately community dwelling iRBD patients’ values and preferences are needed to guide appropriately tailored and individualized prognostic counseling approaches following iRBD diagnosis.